Johnson And Johnson (JNJ) vs Pfizer (PFE)
JNJ leads PFE on the current QuantLink comparison, based on the rows where both companies have available metrics and a fixed comparison direction.
Side-by-side scorecard
As of Jul 9, 2026. Unavailable values are shown as — and excluded from the comparable-metric tally.
| Metric | Johnson & Johnson (JNJ) | Pfizer Inc. (PFE) |
|---|---|---|
| Size | ||
PriceContext only | — | — |
Market capContext only | $623.7B | $138.2B |
| Valuation | ||
P/E ratio | 29.93x | ✓18.41x |
PEG ratio | ✓-6.69x | -3.63x |
Price/book | 7.76x | ✓1.53x |
Price/sales | 6.53x | ✓2.18x |
EV/EBITDA | 19.61x | ✓11.34x |
| Profitability | ||
Gross margin | 69.1% | ✓69.3% |
Operating margin | ✓26.9% | 23.4% |
Net margin | ✓21.8% | 11.8% |
ROIC | ✓14.1% | 6.6% |
ROE | ✓25.9% | 8.3% |
EPS | — | — |
| Leverage | ||
Debt/equity | ✓0.68x | 0.72x |
| Dividend | ||
Dividend yield | — | — |
How the comparison is scored
QuantLink marks a row leader only when both companies have a numeric value and the metric has a fixed comparison direction. Lower values lead on valuation multiples and debt/equity, while higher values lead on profitability and dividend yield.
Price and market capitalization are shown for context only, so they do not receive a leader checkmark and do not affect the tally.